Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Solid Biosciences (SLDB) Net Income towards Common Stockholders: 2017-2024

Historic Net Income towards Common Stockholders for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to -$38.0 million.

  • Solid Biosciences' Net Income towards Common Stockholders fell 84.64% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 24.19%. This contributed to the annual value of -$120.6 million for FY2024, which is 24.19% down from last year.
  • As of Q4 2024, Solid Biosciences' Net Income towards Common Stockholders stood at -$38.0 million, which was down 15.51% from -$32.9 million recorded in Q3 2024.
  • In the past 5 years, Solid Biosciences' Net Income towards Common Stockholders registered a high of -$19.0 million during Q2 2020, and its lowest value of -$38.0 million during Q4 2024.
  • Over the past 3 years, Solid Biosciences' median Net Income towards Common Stockholders value was -$25.3 million (recorded in 2024), while the average stood at -$27.0 million.
  • As far as peak fluctuations go, Solid Biosciences' Net Income towards Common Stockholders soared by 37.62% in 2023, and later slumped by 84.64% in 2024.
  • Solid Biosciences' Net Income towards Common Stockholders (Quarterly) stood at -$21.4 million in 2020, then reached -$33.0 million in 2022, then skyrocketed by 37.62% to -$20.6 million in 2023, then crashed by 84.64% to -$38.0 million in 2024.
  • Its Net Income towards Common Stockholders stands at -$38.0 million for Q4 2024, versus -$32.9 million for Q3 2024 and -$25.3 million for Q2 2024.